FDA Approved: MYDAYIS — Original Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved the original application for MYDAYIS, a mixed amphetamine salts product, for the treatment of attention deficit hyperactivity disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• MYDAYIS (mixed amphetamine salts, extended-release)

Snippet

ORIG AP for MYDAYIS (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE)